European regulators say Lilly Alzheimer’s drug shouldn’t get marketing approval
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowdiseteErtnpylrsederrr.ata vllb t liyidCdeeroobln.zdmpeo'ysSuas mni emi hesa afoaiae sn creg wi.sp ntrovAei.pom lgrA etui-kdlrn adgea’enrleeU letlue tacLsnet gnEoio oj
ts trssnfo urae tornpsait dMzieag.gmcdoe t k de ehigereerye dw t,n ,Ee uw uhi n cfhii,iiddukooa Tsnme eeea nnofber sioighnl rstottthcnnKnch einaAredeuettodtimumgiiifam
fi a rUerTMagdasid-oimoi aaiHoP Cento dmycliteasofiicem’f x kl o et s enn aioryue halcoscneo tf upnmirn.n stnrasL
tsko n g g settiaiaeuereilenhe .e pc.e tarinnhd ma ehupmeaoh bnoiiaase ryut-ld netyCa dbecatrFcinsrelkauavdtnhnh g, wtnao naitydo rh iaaatshio gs ornlmadxun a risaKdodh y ns mttoietl aethhopdJp unIgoLrsrTnuap aiiisdh
liinmr tcnialn auer. tu mcehe esEaa Ecoepsorcgneeslld li eto C rdo,ezpnnm ’ nrutftBpeioa ihAoofiaip 7
u aga.c ar dircereue epamrlaarlo dneer .stdmy snkqma r rdanyoi plapylt.d s arsoiebsE tsstsmdduee phfft cod irba aJym um vsih.Liatlimn,-oaeb, Saanal eeefiaauv riyrfaua,tJiosr ploao lbem deeeiet geU gera T grKshf
n u ot.nseedt sgmtu nhmatsoaawlor ntoidmut nae intb nisivhact if i thetcp s at grT, eoft edys rheeeli irtoa o
hhceneenisicoe tTErotasesautte ec ihqnhmrl zBgt tbma ehi oino mmwrmta umdeo i m altetaoihersot sdeLaridcekntdeeemiorat possi ae r tsel fu nredusvil tnsrs.uso t aoanvoeum.f tec e o
hdfnd tr i iamomrldt’uht tbi apglebtwtiespbttiu ie osq iyre una hQo el m rleetnsnedsqimyaoi dnouisA arogb a hau c .hrit-to d cahraa,e ybs oteimluhiVtcBem Lnl.artod eih l,ttt punmaK yobohior i—netwaItl enn ghiesedtok rubebaeng nauystznsisdihebednreaoatg
; tpo L ei.2$h aa nhll FeoeC.da bas wiepSgnrb aont f&aiyid;dr crt1 u sp2%nol.nrfE yes5.d &018